Literature DB >> 32700285

Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)-a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment.

Nataliia Petryk1, Mykhailo Petryk2.   

Abstract

Due to the fact that modern American and European women postpone childbirth until later in life, they are more likely to face the problem of ovarian insufficiency by the time they are ready to have children. So, the ability to restore the ovarian function safely is crucially important. Our study involved 38 women 31-45 years of age with low ovarian reserves and at least two unsuccessful attempts to receive their oocytes through IVF. The blood from the patients was collected into two BD vacutainers for PRP preparation. The platelet concentration in the PRP was 1 × 106 μl. PRP injections into the ovaries were performed by a gynecologist with a special 25G needle, 20 cm in length, as an ultrasound-guided procedure or a laparoscopic-assisted approach. After PRP treatment, women were tested with several criteria for 12 months. We saw a significant improvement in hormone levels; six healthy babies were born, ten pregnancies were achieved, and four out of the ten were from natural conception. The PRP injections into the ovaries are safe, productive, and a natural treatment that may help women with premature ovarian insufficiency to give birth to their own child. The difference and novelty with our method of ovarian rejuvenation is in obtaining a higher platelet concentration (about 1 × 106 μl), which allows us to achieve long-lasting results, within 12 months, after a single procedure. Additionally, for the first time, we proposed and successfully performed a laparoscopically assisted technique for administering PRP into the ovary.

Entities:  

Keywords:  Anti-Müllerian hormone; Follicle-stimulating hormone; Low ovarian reserve; Luteinizing hormone; Platelet-rich autologous plasma

Mesh:

Year:  2020        PMID: 32700285     DOI: 10.1007/s43032-020-00266-8

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  7 in total

Review 1.  Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action.

Authors:  Serin Seckin; Hadi Ramadan; Marco Mouanness; Michelle Kohansieh; Zaher Merhi
Journal:  J Assist Reprod Genet       Date:  2022-02-17       Impact factor: 3.412

Review 2.  Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature Ovarian Insufficiency.

Authors:  Mara Ulin; Esra Cetin; Elie Hobeika; Rishi Man Chugh; Hang-Soo Park; Sahar Esfandyari; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2021-05-06       Impact factor: 3.060

3.  Effect of intraoperative cell rescue on bleeding related indexes after cesarean section.

Authors:  Yu-Fang Yu; Yong-Dong Cao
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

4.  A new approach of using platelet-rich autologous plasma to increase the ovarian reservoir in a Syrian patient with ovarian insufficiency: A case report.

Authors:  Rami Sabouni; Rand Tarrab; Dania Kalaji; Haitham Abbassi
Journal:  Ann Med Surg (Lond)       Date:  2021-12-11

5.  Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization.

Authors:  Zaher Merhi; Serin Seckin; Marco Mouanness
Journal:  Clin Exp Reprod Med       Date:  2022-08-31

6.  Influence of Autologous In Vitro Activation of Ovaries by Stem Cells and Growth Factors on Endocrine and Reproductive Function of Patients with Ovarian Insufficiency-A Clinical Trial Study.

Authors:  Suada Tinjić; Džihan Abazović; Dušica Ljubić; Danilo Vojvodić; Tatjana Božanović; Mirza Ibrišimović; Sergije Marković; Aleksandar Ljubić
Journal:  Int J Fertil Steril       Date:  2021-06-22

7.  Appraisal of Experimental Methods to Manage Menopause and Infertility: Intraovarian Platelet-Rich Plasma vs. Condensed Platelet-Derived Cytokines.

Authors:  E Scott Sills; Samuel H Wood
Journal:  Medicina (Kaunas)       Date:  2021-12-21       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.